Recurrent transforming UBR5-ZNF423 fusion gene in EBV-associated nasopharyngeal carcinoma

Patent metadata

Field	Value
Publication number	US-9464327-B2
Application number	US-201414188364-A
Country	US
Kind code	B2
Filing date	Feb 24, 2014
Priority date	Mar 14, 2013
Publication date	Oct 11, 2016
Grant date	Oct 11, 2016

Abstract

The present invention provides a method for diagnosing nasopharyngeal cancer in a subject by detecting UBR5-ZNF423 fusion polypeptide or polynucleotide, which is in some cases due to a gene fusion of UBR5-ZNF423. A kit useful for such a method is also provided. In addition, the present invention provides a method for treating nasopharyngeal cancer by eliminating UBR5-ZNF423 gene expression or activity.

First claim

What is claimed is:

1. A UBR5-ZNF423 fusion polypeptide comprising the amino acid sequence set forth in SEQ ID NO:3 and a heterologous tag.

2. A composition comprising the UBR5-ZNF423 fusion polypeptide of claim 1 and a pharmaceutically acceptable excipient.

3. The UBR5-ZNF423 fusion polypeptide of claim 1 , wherein the heterologous tag comprises a detectable label.

Assignees

• Univ Hong Kong Chinese

Inventors

• Lo Kwok-Wai
• To Ka-Fai
• Chung Tin-Yun
• Lung Wai-Ming

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• G01N2333/9015

  Ligases (6) · CPC title

• G01N2800/60

  Complex ways of combining multiple protein biomarkers for diagnosis · CPC title

• C12Q2600/158

  Expression markers · CPC title